I. MODIFIED AGREEMENTS | |||
Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) | Change from original agreement | Terms/Details (Date) |
FEBRUARY 2009 | |||
Ablynx NV (Belgium; BR:ABLX) | Novartis AG (Switzerland) | Extended for another year a drug discovery and development alliance for nanobody-based therapeutics against disease targets that are difficult to address with conventional antibodies or their fragments | As part of the collaboration, Ablynx receives license fees and funding for research and development; Ablynx is eligible for milestone payments and royalties upon commercialization (2/5) |
BioFocus DPI (UK; division of Galapagos; BR:GLPG) | Eli Lilly and Co. | Extended drug discovery agreement until the end of the year | BioFocus will identify active compounds by screening Lilly's library compounds; the agreement, started in March 2005, is focused on discovering new compounds that target specific cellular signal transduction pathways (2/24) |
Palatin Technologies Inc. (AMEX:PTN) | AstraZeneca plc (UK) | Extended exclusive research collaboration and license agreement to discover, develop and commercialize compounds that target melanocortin receptors and a clinical trial sponsored research agreement | Palatin received $4.1M as part of the extension (2/12) |
XOMA Ltd. (XOMA) | Takeda Pharmaceutical Co. Ltd. (Japan) | Expanded collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems | XOMA will receive a $29M expansion fee and may receive potential milestones and royalties on antibody products; XOMA also may incur $7.5M in taxes and other costs related to the expansion (2/10) |
MARCH 2009 | |||
Angiotech Pharmaceuticals Inc. (Canada; ANPI) | Baxter International Inc. | Restructured partnership for Coseal surgical sealant | Angiotech opted to receive $25M in lieu of future milestone and royalty revenues from Baxter, and Baxter gained expanded world-wide rights to the product (3/31) |
Dynavax Technologies Corp. (DVAX) | AstraZeneca plc (UK) | Extended research collaboration until 2010 to develop drugs for asthma and chronic obstructive pulmonary disease based on Dynavax's immunostimulatory sequences | The firms have moved AZD1419, the first candidate, toward the clinic and may start Phase I testing in the second half of this year (3/11) |
EffRx Inc.* | Nycomed A/S (Denmark) | Licensing agreement that will expand the territories for EffRx's EX101 for the treatment of osteoporosis | The deal now covers the whole world, except the U.S., Japan, South African countries and a few other minor markets; EffRx will receive up to $15M in additional up-front and milestone payments (3/30) |
Tekmira Pharmaceuticals Corp. (Canada; TSX:TKM) | Bristol-Myers Squibb Co. | Exercised option to extend through this year the research collaboration between the two companies | The collaboration focuses on validating gene targets using small interfering RNA provided by BMS and employing Tekmira's stable nucleic-acid lipid particle formulations to deliver the siRNA (3/25) |
Vyteris Inc. (OTC BB:VYTR) |
Ferring Pharmaceuticals Inc. (Switzerland) | Agreement to provide additional funding for the first half of the 2009 development budget for a pulsatile delivery of a peptide hormone for treatment of infertility in women | Ferring has committed to pay the first half of the budgeted costs of up to $3.3M, with cash proceeds committed to the infertility project, and Vyteris to fund the second half of the 2009 development budget (3/25) |
APRIL 2009 | |||
Nuevolution A/S* (Denmark) | Merck & Co. Inc. | Agreement to proceed to the second phase of a June 2008 collaboration agreement to apply Nuevolution's Chemetics drug discovery technology to identify novel small-molecule leads against several drug targets | Merck thus gains access to a new multi- million member library of small-molecule leads against several drug targets (4/2) |
II. TERMINATED AGREEMENTS | |||
BioAlliance Pharma SA (France; Paris:BIO) | SpePharm Holdings BV (the Netherlands) | Terminated licensing agreement for the distribution of Loramyc, a muco-adhesive buccal tablet for treating oropharyngeal candidiasis | Details were not disclosed (2/27) |
GTC Biotherapeutics Inc. (GTCB) | LEO Pharma AS (Denmark) | Terminated a 2005 contract for commercialization and development of ATryn in Europe, Canada and the Middle East | GTC is seeking damages from LEO under International Chamber of Commerce arbitration procedures (3/16) |
Micromet Inc. (MITI) | MedImmune Inc. (unit of Astra-Zeneca plc; UK) | Terminated agreement that returns rights in North America to the BiTE antibody candidate, blinatumomab, also known as MT103, to Micromet | Micromet is conducting a Phase II trial to treat acute lymphoblastic leukemia and a Phase I trial to treat non-Hodgkin's lymphoma (3/12) |
Notes: # The information in the chart does not cover agreements between biotech companies or agricultural agreements. * Private companies are indicated with an asterisk.Unless otherwise noted, stock symbols listed are on the Nasdaq market. BR = Brussels Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | |||